Market News & Trends
Inmagene Reports Positive Topline Results of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life for the Treatment of Atopic Dermatitis
Inmagene Biopharmaceuticals reports additional positive topline results from the Phase 2a trial of IMG-007 in patients with moderate-to-severe AD, along with the results of a…
RheumaGen Launches With $15-Million Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases
RheumaGen, Inc. recently announced the close of a $15-million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees. The financing will support…
MoonLake Initiates Three New Clinical Trials & Further Expands Portfolio of Indications for the Nanobody Sonelokimab
MoonLake Immunotherapeutics recently announced patients have been screened in three new trials across three new indications to evaluate sonelokimab, an investigational Nanobody designed to treat…
LB Pharmaceuticals Announces Positive Topline Results From Phase 2 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals Inc. recently announced positive topline results from NOVA, a Phase 2 dose finding trial in adult patients with acute schizophrenia evaluating LB-102, a…
Araris Biotech AG Announces Research Collaboration & Option to License Agreement With Chugai Pharmaceutical Co.
Araris Biotech AG recently announced it has entered a Research Collaboration and Option to License Agreement (RCO) under which Araris will use its proprietary linker-conjugation…
AerWave Completes First-in-Human Study to Advance Disease-Modifying Ultrasound-Based Therapy for COPD & Asthma
AerWave Medical recently announced the successful completion of its first-in-human (FIH) feasibility study of its disease-modifying ultrasound lung denervation therapy for chronic obstructive pulmonary disease (COPD)…
Palvella Therapeutics Announces First Patients Dosed in Phase 2 Trial of QTORIN 3.9% Rapamycin Anhydrous Gel for the Treatment of Cutaneous Venous Malformations
Palvella Therapeutics, Inc. recently announced the first patients have recently been dosed in TOIVA, a multicenter, Phase 2 clinical trial designed to evaluate the safety…
Abzena Strengthens Board With Appointment of Biopharma Industry Leader
Abzena recently announced the appointment of Moncef Slaoui, PhD, to its Board of Directors. A highly accomplished leader in the biopharmaceutical industry with over 40…
Silo Pharma Awarded Patent for Groundbreaking PTSD Treatment
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application 17/954,864 for Pharmacological Prophylactics Against…
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics Inc. recently announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343…
Next-Generation RNA Company Launched by Argobio & University of Southern Denmark
Inverna Therapeutics recently announced its launch as a leading-edge RNA therapeutics company. The Company was co-founded by the University of Southern Denmark and Argobio and…
MBX Biosciences Announces Positive Phase 1 Topline Results for Post-Bariatric Hypoglycemia Treatment
MBX Biosciences, Inc. recently announced positive results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of MBX 1416…
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
RESTEM recently announced the US FDA has granted Fast Track designation for Restem-L, the company’s umbilical cord outer lining stem cells (ULSCs) program for the…
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
Annovis Bio Inc. recently announced the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in…
QUANTRO Therapeutics Achieves Breakthrough in Transcriptomic Drug Discovery
QUANTRO Therapeutics recently announced it has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple…
Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities
Molex, a parent to Phillips Medisize, recently announced it has completed, through an affiliate, the previously announced acquisition of Vectura Group Ltd. (Vectura) from Vectura…
Fortress Biotech & Cyprium Therapeutics Announce FDA Acceptance & Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Fortress Biotech, Inc. and its majority-owned subsidiary, Cyprium Therapeutics, Inc. recently announced the acceptance for review of the New Drug Application (NDA) by the US…
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. recently announced China’s National Medical Products Administration (NMPA) has approved taletrectinib for the treatment of adult patients with locally advanced or metastatic…
Gaelic Laboratories Announces Expansion Enabling Access to Growing Middle East Market
Gaelic Laboratories has established a subsidiary in the UAE, enabling access to the Middle East market – both for Gaelic Laboratories and its marketing partners…
Atavistik Bio Announces Research Collaboration With Pfizer
Atavistik Bio recently announced it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant…
